Keybank National Association Has Cut Astrazeneca Plc (AZN) Holding; Shorts at TELOS CORPORATION PREFERRED STOCK (TLSRP) Raised By 2300%

AstraZeneca PLC (NYSE:AZN) Logo

Keybank National Association decreased Astrazeneca Plc (AZN) stake by 35.14% reported in 2018Q3 SEC filing. Keybank National Association sold 28,385 shares as Astrazeneca Plc (AZN)’s stock rose 1.75%. The Keybank National Association holds 52,383 shares with $2.07 million value, down from 80,768 last quarter. Astrazeneca Plc now has $94.01 billion valuation. The stock decreased 1.03% or $0.39 during the last trading session, reaching $36.81. About 2.04M shares traded. AstraZeneca PLC (NYSE:AZN) has risen 19.21% since February 13, 2018 and is uptrending. It has outperformed by 19.21% the S&P500. Some Historical AZN News: 23/05/2018 – American Heart Association: Important expansion of in-hospital cardiovascular care program to drive improved patient outcomes across China; 02/04/2018 – MYRIAD GENETICS INC – ASTRAZENECA AND MERCK ARE SEEKING APPROVAL OF LYNPARZA IN JAPAN FOR TREATING PATIENTS WITH BRCA-MUTATED METASTATIC BREAST CANCER; 16/04/2018 – G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Sma; 27/04/2018 – AstraZeneca: EU Recommends Change to Tagrisso Marketing Authorisation; 27/05/2018 – LUYE PHARMA BUYS ASTRAZENECA’S SIGNATURE PRODUCTS SEROQUEL,; 18/04/2018 – ASTRAZENECA: FDA OKS TAGRISSO AS 1ST-LINE TREATMENT FOR NSCLC; 07/05/2018 – Procella Therapeutics and Smartwise Enter Collaboration With AstraZeneca to Develop Novel Cardiovascular and Catheter-based The; 18/04/2018 – US FDA Approves TAGRISSO┬« (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer; 25/05/2018 – ASTRAZENECA PLC AZN.L : CREDIT SUISSE RAISES TARGET PRICE TO 5900P FROM 5800P; 18/05/2018 – ASTRAZENECA PLC AZN.L – PRODUCT SALES PERFORMANCE BENEFITTED FROM STRONG LAUNCHES

TELOS CORPORATION PREFERRED STOCK (OTCMKTS:TLSRP) had an increase of 2300% in short interest. TLSRP’s SI was 2,400 shares in February as released by FINRA. Its up 2300% from 100 shares previously. With 2,200 avg volume, 1 days are for TELOS CORPORATION PREFERRED STOCK (OTCMKTS:TLSRP)’s short sellers to cover TLSRP’s short positions. It closed at $24.99 lastly. It is down 0.00% since February 13, 2018 and is . It has by 0.00% the S&P500.

Keybank National Association increased Abbott Labs (NYSE:ABT) stake by 18,107 shares to 1.51M valued at $110.88 million in 2018Q3. It also upped Aptiv Plc stake by 8,039 shares and now owns 10,446 shares. Gilead Sciences Inc (NASDAQ:GILD) was raised too.

More important recent AstraZeneca PLC (NYSE:AZN) news were published by: Seekingalpha.com which released: “European advisory group backs AstraZeneca’s Forxiga in T1D – Seeking Alpha” on February 01, 2019, also Seekingalpha.com published article titled: “AstraZeneca to promote Luye Pharma cholesterol med in China – Seeking Alpha”, Investorplace.com published: “Sell Amarin Stock on the Recent Takeover Rumors Rally – Investorplace.com” on January 14, 2019. More interesting news about AstraZeneca PLC (NYSE:AZN) was released by: 247Wallst.com and their article: “Top Analyst Upgrades and Downgrades: Avaya, AstraZeneca, HD Supply, HubSpot, Intel, Norfolk Southern, Ultimate Software, Valero Energy and More – 24/7 Wall St.” with publication date: January 25, 2019.

Among 4 analysts covering AstraZeneca (NYSE:AZN), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. AstraZeneca had 5 analyst reports since August 16, 2018 according to SRatingsIntel. The stock of AstraZeneca PLC (NYSE:AZN) has “Hold” rating given on Thursday, August 16 by Jefferies. The company was downgraded on Monday, November 19 by Investec. Jefferies reinitiated the stock with “Hold” rating in Tuesday, December 11 report.

AstraZeneca PLC (NYSE:AZN) Ratings Chart